Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and non-pregnant, non-lactating women 45 years of age or older~* Able to give informed consent and complete scheduled visits~* Mild-moderate bilateral lower extremity peripheral arterial disease as defined by an ankle-brachial index (ABI measurement of 0.6-0.9. If a subject has baseline claudication symptoms, the symptoms must be stable for the 3 months preceding enrollment.~* History of hypertension. Blood pressure at the screening visit must be ≤160/100 mmHg and ≥100/60 mmHg for all subjects. If a subject is currently prescribed beta-blocker therapy, BP at the screening visit must be ≤140/90 mmHg. In addition, heart rate must be ≥55 beats per minute if currently prescribed a beta-blocker and ≤60 beats per minute if not currently prescribed a beta-blocker.~* At least moderate risk for CAD.~Exclusion Criteria:~* Participation in another clinical trial~* Ongoing ischemic (resting) limb pain, or lower extremity ulceration due to arterial insufficiency, or an ABI indicating \<0.6 indicating disease potentially requiring revascularization~* History of limb or digit amputation due to arterial insufficiency~* Revascularization of peripheral vessels within the preceding 6 months~* Uncontrolled hypertension as defined by systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg~* Contraindication or allergy to beta blocker therapy~* History of myocardial infarction , coronary revascularization, or a cerebrovascular event within the preceding 6 months~* Class III or IV angina~* Current or past history of New York Heart Association (NYHA) class III or IV heart failure~* Inability to walk on a treadmill for any reason~* Regular use of nitroglycerin or nitrates including oral, transdermal ointment or patch, or sublingual, translingual spray and/or combination agents containing nitrates~* Active liver, pulmonary, infectious or inflammatory process~* History of malignancy within preceding 5 years (excluding basal or squamous cell skin cancer)~* History of any other condition that, in the opinion of the investigators, renders it unsafe for the subject to be enrolled

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nebivolol (Type: EXPERIMENTAL): nebivolol 1 to 4 capsules daily
- metoprolol succinate (Type: ACTIVE_COMPARATOR): metoprolol 1 to 4 capsules daily

Based on this trial design, predict the completion outcome and termination type (if applicable).